The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Patents, Royalties, Other Intellectual Property - OncoResponse Inc
Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors.
 
Mohamad Salkeni
Employment - Next Oncology; Virginia Cancer Specialists
Stock and Other Ownership Interests - Next Oncology
Honoraria - Healthcasts
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - 1ST Biotherapeutics (Inst); Acrivon Therapeutics (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); Compugen (Inst); CrystalGenomics (Inst); Daiichi Sankyo US (Inst); Epizyme (Inst); Exelixis (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Inmune Bio (Inst); Ionova (Inst); Kronos Bio (Inst); MBrace Therapeutics (Inst); Merck (Inst); Nested Therapeutics (Inst); OncoResponse (Inst); Oncternal Therapeutics (Inst); Pasithea Therapeutics (Inst); Pathos (Inst); Pheon Therapeutics (Inst); Prelude Therapeutics (Inst); Schrodinger (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Tarus Therapeutics (Inst)
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Day One Biopharmaceuticals (Inst); Dicerna (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); IconOVir Bio (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Symphogen (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)
 
Andrae Vandross
Employment - Next Oncology; Texas Oncology
Consulting or Advisory Role - Abbvie (Inst); Boxer Capital (Inst); NiKang Therapeutics (Inst); Pliant Pharma
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); BiOneCure (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); Deciphera (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); IMPAC Medical Systems (Inst); Kirilys Therapeutics (Inst); Kura Oncology (Inst); Lyvgen Biopharma (Inst); MBRACE (Inst); Medikine (Inst); Nanjing (Inst); Nested Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); OncoResponse (Inst); Pliant (Inst); PMV Pharma (Inst); Sirnaomics (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Vividion Therapeutics (Inst); Xilio Therapeutics (Inst); Yufan Biotechnologies (Inst); ZielBio (Inst); Zumutor Biologics (Inst)
 
Kamal Puri
No Relationships to Disclose
 
Myriam Bouchlaka
Employment - Virginia Mason Franciscan Health (I)
Stock and Other Ownership Interests - Moderna Therapeutics (I); OncoResponse Inc; Pfizer (I)
Patents, Royalties, Other Intellectual Property - Pending patents or patents with OncoResponse Inc
 
Nenad Sarapa
Employment - Bexon Clinical Consulting
 
Lesley Skingley
No Relationships to Disclose
 
Mike Yefimenko
Employment - Bexon Clinical Consulting
 
Alice Bexon
Employment - Bexon Clinical Consulting
Leadership - March Biosciences; Sapience Therapeutics; Vyriad
Stock and Other Ownership Interests - AI Proteins, Inc; Sapience Therapeutics; Vyriad
Consulting or Advisory Role - March Biosciences; RS Oncology; Sapience Therapeutics; Vyriad
Patents, Royalties, Other Intellectual Property - Patent for AST-008 use in combination with checkpoint inhibitors; Patent for methods of treating cancer with combination therapy (Merck KGaA/PFizer/Vyriad); Patents for Sapience know-how relative to ST101
Travel, Accommodations, Expenses - RS Oncology; Sapience Therapeutics; Vyriad
 
Damien Cronier
Leadership - DMC Biopharma SAS
Stock and Other Ownership Interests - Eli ~Lilly and Company
Consulting or Advisory Role - Bexon Clinical Consulting
 
Shiraj Sen
No Relationships to Disclose